Context Therapeutics drops CT-95 bispecific T-cell engager to stretch cash runway to 2027

Context Therapeutics announced it is halting development of its bispecific T-cell engager CT-95.

The company acquired CT-95 in 2024 for $3.7 million and began dosing patients in a phase 1 trial in April 2025, with interim data originally slated for September.

With cash projected to fall to $43 million by the end of June and the CT-95 trial costing $2.9 million in the first half of 2026, the biotech decided to pull the plug to preserve cash and extend its runway into 2027.

The decision also removes Context from direct competition with Amgen’s similar T-cell engager program, which has faced enrollment challenges and appears to be on hold.